ReviewNeurotoxicity research2011
Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?
Review in Neurotoxicity research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Association of cholesterol and glycemic state biomarkers with phenotypic variation and Parkinson's disease progression: The Oxford Discovery cohort.Journal of Parkinson's disease · 2025Article
- Association of Hemispheric Asymmetry of Dopamine-Transporter Binding with Risk of Parkinsonian Depression.Movement disorders clinical practice · 2025Article
- Disrupted pattern of rich-club organization in structural brain network from prediabetes to diabetes: A population-based study.Human brain mapping · 2024Article
- Frailty and Parkinson's disease: the role of diabetes mellitus.Frontiers in medicine · 2024Review
- The Role of Steroidomics in the Diagnosis of Alzheimer's Disease and Type 2 Diabetes Mellitus.International journal of molecular sciences · 2023Article
- Parkinson and depression: review and outlook.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- InNutrients · 2018Article
- Lychee seed extract protects against neuronal injury and improves cognitive function in rats with type II diabetes mellitus with cognitive impairment.International journal of molecular medicine · 2018Article
- Disease-Related Variables and Depression Among Iranian Patients with Parkinson Disease.Iranian Red Crescent medical journal · 2015Article
- Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.Endocrinology · 2014Article
- BDNF mediates adaptive brain and body responses to energetic challenges.Trends in endocrinology and metabolism: TEM · 2014Review
- Long-term corticosterone exposure decreases insulin sensitivity and induces depressive-like behaviour in the C57BL/6NCrl mouse.PloS one · 2014Article
- The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.Neuromolecular medicine · 2013Article
- Mild cognitive impairment in Parkinson disease: heterogenous mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2013Review
- Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways.Journal of neural transmission (Vienna, Austria : 1996) · 2013Article
- NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice.Psychopharmacology · 2012Article
- Sleep disturbances in Alzheimer's and Parkinson's diseases.Neuromolecular medicine · 2012Review
- Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase.CNS & neurological disorders drug targets · 2012Review
- Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is ample evidence that impairments in the hypothalamic-pituitary-adrenal (HPA) axis are of etiopathobiochemical importance in a subgroup of patients with "depression", causing hypercortisolaemia as major metabolic effect. Chronic hypercortisolaemia causes insulin resistance. Therefore, it is not surprising that epidemiological studies demonstrate an association of "depression" with diabetes type II and vice versa. Chronic stress and hypercortisolaemia are conditions, which have been suggested to be causal for Alzheimer's disease (AD) as brain insulin resistance is associated with β-Amyloid-accumulation and hyperphosphorylation of tau-protein. Depression is one of the significant symptomatology preceding AD. It is however, not known whether "depression" associated with hypercortisolaemia is the subgroup at risk for AD. In contrast to a subgroup of "depression" and to AD, in Parkinson's disease (PD) there is only weak evidence for an association with diabetes type II and insulin resistance. As "depression" is preceding PD in up to half of such patients, it remains to be elucidated whether this is a subgroup of depressed patients, which is not associated with disturbances of the HPA axis and hypercortisolaemia. Improved clinical and biochemical/molecular knowledge about "depression" associated with AD and PD in comparison to "pure" depression might lead to improved therapeutic strategies and even drug development focusing subtypes of "depression".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.